Stock Track | Neuren Pharmaceuticals Soars 5.12% Intraday as Daybue Stix Becomes Broadly Available in US

Stock Track

Apr 08

Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.

The sharp price increase is directly linked to the company's announcement that Daybue Stix, its treatment for Rett Syndrome, is now broadly available in the United States. This expanded market access is a major commercial milestone, potentially increasing the product's reach to patients and driving future revenue growth for the pharmaceutical company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1139715255"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139715255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139715255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 08:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139715255","market":"nz","top_or_hot":-1,"title":"Stock Track | Neuren Pharmaceuticals Soars 5.12% Intraday as Daybue Stix Becomes Broadly Available in US","media":"Stock Track","content":"<p>Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.</p><p>The sharp price increase is directly linked to the company's announcement that Daybue Stix, its treatment for Rett Syndrome, is now broadly available in the United States. This expanded market access is a major commercial milestone, potentially increasing the product's reach to patients and driving future revenue growth for the pharmaceutical company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Neuren Pharmaceuticals Soars 5.12% Intraday as Daybue Stix Becomes Broadly Available in US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Neuren Pharmaceuticals Soars 5.12% Intraday as Daybue Stix Becomes Broadly Available in US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-08 08:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.</p><p>The sharp price increase is directly linked to the company's announcement that Daybue Stix, its treatment for Rett Syndrome, is now broadly available in the United States. This expanded market access is a major commercial milestone, potentially increasing the product's reach to patients and driving future revenue growth for the pharmaceutical company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1139715255","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139715255","pubTimestamp":1775606846,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.The sharp price increase is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Neuren Pharmaceuticals盘中大涨5.12%Daybue Stix在美国广泛上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1},"content_text":"Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.The sharp price increase is directly linked to the company's announcement that Daybue Stix, its treatment for Rett Syndrome, is now broadly available in the United States. This expanded market access is a major commercial milestone, potentially increasing the product's reach to patients and driving future revenue growth for the pharmaceutical company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}